Birth Defects Prevented by Folic Acid
Birth Defects & Vitamins
TOOK THE FDA SO LONG TO COME OUT IN FAVOR OF FOLIC ACID?
Folic acid (or folate) is frequently referred to in the news media, so I will make some comments about it.
Folic acid is an artifact of chemical isolation. Folic acid is pteroylglutamic acid. This active molecule is a partially degraded, fully oxidized derivative of the folates. Virtually no folic acid exists in either plant or animal tissues. But the folates do.
Folic acid is an inexpensive chemical with a vitamin-like action. One can buy at retail 250 tablets containing 800 micrograms of good quality folic acid for about $6.00. These tablets contain four times the folic acid in today's RDA's (recommended daily allowance). One tablet costs a little over two cents.
Who is most susceptible to general folic acid deficiencies? Pregnant woman, fetuses, premature infants, and elderly people. Women with a systemic folic acid deficiency can develop in addition to other health problems, pre-cancerous changes in the uterine cervix. In addition. some women (users of oral contraceptive agents or smokers) who do not have a systemic folic acid deficiency can develop areas of localized folic acid deficiency in the uterine cervix. Areas of localized folic acid deficiency on the uterine cervix also may become pre-cancerous. Pre-cancer in both types of women, can become cancer. However, the administration of adequate amounts of inexpensive folic acid can effect a cure of the precancerous areas. Then, perhaps the woman may be able to change her diet to include foods rich in folates and sustain such a cure. But it is often hard for a woman to make a sustained improvement in diet. Poor women simply cannot afford the improved diet. In both such types of women, it would seem wise to use inexpensive, adequate pill-a-day folic acid maintenance therapy in addition to as good a diet as they can afford and get themselves to eat..
A folate deficiency in a pregnant woman may cause a special kind of anemia, a premature separation of the placenta, spontaneous abortion, bleeding, an abnormal fetus including those with a neural tube defect, anacephaly, spina bifida and low weight babies. Not only do these sad events cause misery to the mother, father and family but they simultaneously cause a large drain on medical resources as well as an enormous economic drain on Medicaid and on other sources for financing medical care. It would appear that these complications of pregnancy can be largely prevented by good nutrition and appropriate folic acid supplementation for the entire duration of the pregnancy from conception onward. And, this leads me to comment on the FDA's (initial) rejection(s) of an application for approval of the use of folic acid therapy for the prevention of neural tube defects as being premature.
The FDA is charged with making sure that the drugs they approve for prescription use are both safe and effective for specific therapeutic use.
The FDA has recently publicized a change in policy. It now plans to speed up the new drug approval process. This will enable giant pharmaceutical companies to sell expensive drugs with many side effects much earlier than is now possible, which will result in less careful scrutiny of the safety and efficacy of such new drugs,
Nutritional substances such as vitamins and minerals are not drugs. Folic acid is a vitamin. However, there is a section of the FDA regulations that states that any substance can be considered to be a drug if a claim is made that it can improve function or structure in an individual or prevent illness. Because of this, folic acid was legally characterized as a drug, the sponsor had to subject folic acid to the regulations governing the application of a new drug application.
The FDA (had previously) rejected a new drug applications for the use of folic acid intended to prevent neural tube defects in the fetus of a pregnant woman who had such a tragic event in a previous pregnancy. (For years) they had considered this New Drug Application to be premature. This is a way of saying that the FDA considers the data submitted in the folic acid New Drug Application was inadequate and that the sponsor must spend time, possibly years, gathering more data. (Editor’s note: This is precisely what indeed happened with folic acid. See note below.) In the meantime, women who have had the misfortune to have had a fetus with a neural tube disorder in a previous pregnancy could not, for a long time, legally be prescribed folic acid with the view of possibly reducing her risk of having another neural tube defect fetus in future pregnancies,
ABOUT THE SAFETY OF
Even a very high daily oral dose (10 milligrams, which is 10,000 mcg) that is 50 times the present RDA (Recommended Daily Allowance) taken by 27 non-pregnant women for four months was safe and there were no adverse side effects. The much lower oral doses commonly used in treatment of folic acid deficiencies are also safe and effective.
There are no folic acid adverse side effects excepting the following:
(1) folic acid in huge doses administered to epileptic persons may block the anti-epileptic action of their drugs and cause them to have an increase in epileptic attacks (this is unlikely to occur with lower doses of folic acid);
(2) it may rarely decrease zinc absorption of zinc but this does not lower blood zinc levels because of decreased urinary excretion of zinc, and
(3) the patient have concurrent deficiency in both vitamin B 12 and folic acid, a condition that requires concomitant treatment with both vitamin B12 and folic acid. Therefore, folic acid alone cannot be effective.
Thus, folic acid is safer than most of the drugs, if not all the drugs, the FDA has approved for prescription use.
ABOUT THE PROBABLE
EFFECTIVENESS OF FOLIC ACID IN THE PREVENTION OF NEURAL TUBE DEFECTS IN THE
Neural tube defects are terrible complications of pregnancy. A mother who has had this calamity happen to her infant in a previous pregnancy is at considerable risk of having it happen again in subsequent pregnancies.
Many published reports in the medical literature indicate that giving such a woman folic acid in sufficient amounts can greatly lower the risk of recurrences of such extremely damaged fetuses. Some other medical reports disagree. A meta-analysis of all these published papers would probably show that there is enough favorable evidence to show that folic acid can reduce the risk of having a fetus damaged by neural tube defects. In view of all the circumstances, the FDA should give this application provisional approval to since folic acid is an exceedingly safe vitamin.
I am now suggesting how such provisional approval could get the FDA the additional data they want and currently not deprive women at risk of having neural tube defects infants of possible freedom from the recurrence of this calamity through the use of folic acid.
This provisional approval should be subject to the following conditions:
(a) that the non-epileptic woman who has had a previous fetus with neural tube defects start the agreed upon dose of folic acid before conception and continue it throughout her entire pregnancy
(b) that she will agree not to indulge in alcohol before conception and throughout her entire pregnancy and if she does, she will inform her physician how much and how often she partakes of alcohol (alcohol will negate folic acid action)
(c) the obstetrician or nurse midwife who delivers the infant will make a full report about the pattern of folic acid oral usage, whether or not alcohol has been indulged in during the pregnancy and the amounts and frequency of intake, and the condition of the infant on birth to the FDA.
The data on controls (women who have had neural tube defect babies in a prior pregnancy and who have become pregnant again but who did not take folic acid during the current pregnancy) should be collected under the direction of the Surgeon General of the U.S. Public Health Service, who could make it mandatory that that all hospitals which supply obstetric care in the United States compile data report the condition of every baby at birth born to a mother who had not been treated with folic acid during her pregnancy but has had a previous pregnancy ending with a neural tube defect infant. This data would give some reliable measure of how great the risk is of having subsequent neural tube defect babies when folic acid treatment was not given during the pregnancy. This information combined with the prospective information reported to the FDA on the incidence of neural tube defect babies occurring in women treated with folic acid, in turn, would make it possible to assess accurately how effective folic acid is in lowering the risk of occurrence of such tragedies.
(Editor’s note: FDA did ultimately approve folic acid as preventive for neural tube defects such as spina bifida. It took them almost ten years to do so. In each of those years, at least 1,200 babies were born with neural tube defects. That makes some 12,000 birth defects that FDA failed to prevent because of unwarranted caution over a substance that is vastly safer than any drug that they have ever approved.)
(To order a mint-condition, hardcover copy of the rare, original 1949 edition of Dr. Kaufman’s arthritis treatment book, The Common Form of Joint Dysfunction (194 pages plus references), please click here.)
AN IMPORTANT NOTE: This page is not in any way offered as prescription, diagnosis nor treatment for any disease, illness, infirmity or physical condition. Any form of self-treatment or alternative health program necessarily must involve an individual's acceptance of some risk, and no one should assume otherwise. Persons needing medical care should obtain it from a physician. Consult your doctor before making any health decision.
Neither the author nor the webmaster has authorized the use of their names or the use of any material contained within in connection with the sale, promotion or advertising of any product or apparatus. Single-copy reproduction for individual, non-commercial use is permitted providing no alterations of content are made, and credit is given.